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A B S T R A C T
Introduction: In patients with diffuse large B-cell lymphoma (DLBCL) socioeconomic status (SES) is
associated with outcome in several population-based studies. The aim of this study was to further
investigate the existence of disparities in treatment and survival.
Methods: A population-based cohort study was performed including 343 consecutive patients with
DLBCL, diagnosed between 2005 and 2012, in the North-west of the Netherlands. SES was based on the
socioeconomic position within the Netherlands by use of postal code and categorized as low,
intermediate or high. With multivariable logistic regression and Cox proportional hazard models the
association between SES and respectively treatment and overall survival (OS) was evaluated.
Results: Two-third of patients was positioned in low SES. Irrespective of SES an equal proportion of
patients received standard immunochemotherapy. SES was not a signiﬁcant risk indicator for OS
(intermediate versus low SES: hazard ratio (HR) 1.31 (95%CI 0.78–2.18); high versus low SES: HR 0.83 (95%
CI 0.48–1.46)). The mortality risk remained signiﬁcantly increased with higher age, advanced
performance status, elevated LDH and presence of comorbidity.
Conclusion: Within the setting of free access to health care, in this cohort of patients with DLBCL no
disparities in treatment and survival were seen in those with lower SES.
© 2017 Elsevier Ltd. All rights reserved.
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The survival of patients with diffuse large B-cell lymphoma
(DLBCL) has substantially improved since the introduction of
rituximab, with an approximate 20% increase in 5-year overall
survival (OS) in randomized controlled trials (RCT) [1]. This
improvement in OS is also shown in an unselected DLBCL patient
population from a large Dutch population-based cohort study [2].
In the rituximab-era, clinical prognostic factors that are incorpo-
rated in the International Prognostic Index (IPI) score are still valid
to determine outcome of patients [3].
K. Boslooper et al. / Cancer Epidemiology 48 (2017) 110–116 111Besides these ‘classic’ prognostic factors, several population-
based studies report disparities in survival of non-Hodgkin
lymphoma (NHL) patients with low socioeconomic status (SES),
with more advanced disease at time of diagnosis [4], the presence
of more comorbidity that may interfere with intensive treatment
[5–8] and possible inequalities in treatment [9,10]. These
associations may be explained by several social factors, including
a delay in seeking medical advice, inadequate insurance coverage
and inability to cover other contributing costs, resulting in
inequalities in health care access [7,11,12]. However, information
on the treatment given and whether standard immunochemo-
therapy was initiated and ﬁnalized is not thoroughly documented
in previous studies. In the Netherlands, an insurance coverage is
obligatory for all inhabitants since 2006. Although this provides in
an equal access to health care services, it is not clear whether this
equal access sufﬁciently provides in optimal treatment across all
socioeconomic groups. Other factors, such as the presence of more
comorbidity, may also interfere with optimal therapy in patients
with low SES [12].Table 1
Baseline characteristics and treatment of the 343 patients with DLBCL, diagnosed betw
Total (N = 343) High SE
N % % 
Age
<60 92 27 36 
60–79 184 54 51 
80 67 19 13 
Median age (in years) 69 65 
Gender
male 178 52 57 
Place of residence
urban 114 33 36 
rural 216 63 64 
missing 13 4 – 
Ann Arbor stage
1 85 25 27 
2–4 250 73 66 
missing 8 2 7 
Performance status
0–1 265 77 60 
2 66 19 31*
missing 12 4 9 
IPI
0–1 123 36 36 
2 77 22 19 
3 74 22 21 
4–5 54 16 15 
missing 15 4 9 
CCI
0–1 278 81 79 
2 64 19 19 
missing 1 – 2 
Treatment
standard ICT 293 85 85 
other ICT 12 4 2 
other supportive care 37 11 13 
missing 1 – – 
Standard ICT completed 249 85 80 
Radiotherapy 110 31 32 
*Signiﬁcant difference p < 0.05.
Abbreviations: LDH: lactate dehydrogenase; IPI: International Prognostic Index; SES: soci
on the 4-digit postal code; ICT: immunochemotherapy; Standard ICT: R-CHOP21 or R-CH
not applicable.
SES data was missing for 14 patients.An observational, population-cohort study including a consecu-
tive series of patients was designed to investigate the association
between SES, treatment and outcome in the Netherlands, a country
with equal health-care access. The aim was to examine if treatment
disparities were present in the use of standard immunochemother-
apy and whether socioeconomic disparities in outcome could be
attributed to either the treatment given or to differences in other
factors, such as the traditional prognostic factors and comorbidity.
2. Methods
2.1. Hemobase
Starting in 2005, all consecutive patients from the ﬁve medical
centres in Friesland, a province in the Northern part of the
Netherlands with 650,000 inhabitants, diagnosed with a hemato-
logical malignancy were prospectively registered in a clinical
database, HemoBase, for objective assessment of clinical param-
eters and for research purpose. HemoBase is a web-based,een 2005 and 2012, stratiﬁed for socioeconomic status.






























oeconomic status at neighborhoodlevel classiﬁed as low, intermediate or high based
OP14 (rituximab-cyclophosphamide, doxorubicin, vincristin and prednisone); n/a:
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speciﬁcally designed by professionals for the hemato-oncology.
With direct registration by professionals involved in the diagnostic
work-up and treatment, the database is representative for the
incidence, characteristics and treatment of patients with a
hematological malignancy in the complete Friesland area [13].
2.2. Study population
In the current study all consecutive patients at age 18 years
diagnosed with DLBCL between 1 January 2005 until 31 December
2012 were included. Excluded were: patients (n = 77) with
transformation from low-grade lymphoma into DLBCL, recurrent
disease, cutaneous DLBCL, primary DLBCL of central nerve system
and primary effusion lymphoma. To ensure that all diagnoses of
DLBCL were captured, the HemoBase database was compared with
the nationwide Netherlands Cancer Registry; no discrepancies
were found. Approval was obtained from the Medical Ethics
Review Committee from Medical Centre Leeuwarden for this
observational study. Informed consent was waived in accordance
with Dutch regulations.
2.3. Study variables
2.3.1. Patient- and disease characteristics
All relevant data of clinical characteristics and prognostic
factors (Table 1) were retrieved from HemoBase and local patient
records. Comorbidity data at time of diagnosis was collected
retrospectively and scored by using the Charlson Comorbidity
Index (CCI) [14]. To minimize the risk for incomplete data, the CCI
of all patients were discussed with the treating clinicians. This way,
we ensured the presented data is a correct reﬂection of the actual
CCI. A high comorbidity score was deﬁned as CCI  2 [8]. The
International Prognostic Index (IPI) was calculated for every
patient. The histological diagnoses were made on the ﬁrst nodal or
extranodal biopsy according to the World Health Organization
classiﬁcation [15]. Information about the degree of urbanization
was obtained from “Statistics Netherlands (CBS)”.
2.3.2. Treatment
Treatment was documented in all patients, and the main
treatment modality was categorized in either standard immuno-
chemotherapy, deﬁned as R-CHOP21 or R-CHOP14, other (subop-
timal) immunochemotherapeutic regimes or palliative treatment
(supportive care or radiotherapy only). Of all patients who received
immunochemotherapy, the number of cycles, the administration
of granulocyte-colony stimulating factor (G-CSF) and the applica-
tion of additional radiotherapy was documented.
2.3.3. SES
SES was deﬁned on the level of neighborhood and at the level of
district.
From 1998 neighborhood SES data are available for each four-
digit postal code area with more than one hundred households and
provided by the “Sociaal Cultureel Planbureau (SCP)”, a govern-
mental organization [16]. These neighborhood SES data are based
on four parameters: (1) mean annual income per household, (2)
the percentage of households with a low income, (3) proportion of
households with low education level and (4) percentage of
unemployment. These variables are used as a combined score
and the data is updated every four years. To determine the
socioeconomic position of a neighborhood within the Netherlands,
the scores are ranked. Based on these rank numbers SES is divided
into quintiles and categorized into three groups: high (ﬁrst and
second quintile), intermediate (third quintile) and low (fourth and
ﬁfth quintile) SES. Neighborhood SES based on postal code iswidely used in previous Dutch studies [17–21] and the main
analysis was performed with these data. To evaluate the impact of
this deﬁnition of SES a second analysis was performed in which SES
was deﬁned at the level of quarters, which are smaller areas than
the 4-digit postal code region. The quarter level SES is a combined
score based on income level, degree of unemployment and
percentage of house ownership and also categorized in high,
intermediate and low SES [22].
2.4. Follow-up
Follow-up was completed until 01 July 2014. Tumor responses in
patients who completedR-CHOPtherapy were classiﬁedascomplete
remission (CR), partial response (PR), stable disease (SD), or
progressive disease (PD) according to the International Working
Group [23]. Recurrent or progressive disease was documented, and
treatment accordingly. Survival time (in months) was deﬁned as the
time period from date of diagnosis until date of death or date of last
follow-up. In case of death, causality with disease or treatment was
recorded.
2.5. Statistical analysis
For describing differences between SES groups Chi-square tests
were used. The inﬂuence of SES on the initiation of standard
immunochemotherapy and ability to complete treatment was
evaluated by use of multivariable logistic regression models, with
calculation of odds ratios (OR), corresponding 95% conﬁdence
intervals (95% CI) and adjustment for other predictors when
applicable.
The following variables were evaluated as potential predictors
for OS: gender, age, Ann-Arbor stage, presence of extranodal
disease, performance status (PS), elevated lactate dehydrogenase
(LDH), IPI, CCI, SES and place of residence. To identify the impact of
these variables on OS the Cox proportional hazard modeling was
used. Resulting risk estimates are presented as hazard ratios (HR)
with related 95% CI. Within the multivariable analysis a backward
strategy was used, starting with the full model in which variables
signiﬁcant at a P-value <0.10 with reduction to a ﬁnal model
ending with all variables at a level of P < 0.05. Given the aim of the
study, SES remained included in the ﬁnal model.
All analyses were performed using commercially available
computer software (Statistical Analysis System version 9.3; SAS
Institute, Cary, NC).
3. Results
343 patients with DLBCL were eligible for the study. The baseline
characteristics are depicted in Table 1. Two-third of the patients was
classiﬁed as low SES. SES data was missing in 14 patients. Comparing
the SES subgroups, only performance status was signiﬁcantly
different at baseline, with more advanced performance status
(PS  2) in patients with high SES (Chi-square P = 0.03).
Immunochemotherapy was initiated in 305 patients (89%) and
the majority (85%) received the standard regime with either R-
CHOP21 or R-CHOP14. Of those treated with standard immuno-
chemotherapy, 85% of the patients completed treatment with
either 6 or 8 cycles or in case of stage I disease 3 or 4 cycles
followed by radiotherapy. Slightly more than one-third received G-
SCF as supportive care during immunochemotherapy. Overall, 31%
of the patients received radiotherapy with 3% as sole palliative
treatment. In the other 28% (n = 98) of patients who received
radiotherapy, 59% (n = 58) had stage I disease and 41% (n = 40)
suffered from advanced disease without CR after immunochemo-
therapy. In 251 patients (82%) either CR or PR was documented
during or after ﬁnalizing immunochemotherapy. In 75% of the
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performed. At the time of analysis 138 patients (40%) had died and
the majority of deaths were disease-related (58%; Table 2).
As shown in Table 3, the likelihood to receive standard
immunochemotherapy and the ability to complete treatment
did not differ between patients with low, intermediate and high
neighborhood SES. A decreasing odds ratio was seen in use of
standard immunochemotherapy and the ability to complete
treatment with increasing age, PS  2, and CCI  2.
The median duration of follow-up was 55 months (95% CI 48–58
months). Median survival time was 90 months for the whole
population. The variables signiﬁcantly increasing mortality risk are
depicted in Table 4. At univariable analysis, the classic prognosticTable 3
Predictors for initiation and completion of standard immunochemotherapy (ICT) in pa
Standard ICT initiated N = 293 
Crude OR (95% CI) Adjusted OR (95
SES
low 1 1 
intermediate 0.95 (0.39–2.30) 0.99 (0.29–3.38)
high 1.02 (0.43–2.47) 2.08 (0.53–8.42)
Age
<60 1 1 
60–79 0.36 (0.10–1.26) 0.35 (0.07–1.75)
80 0.04 (0.01–0.15) 0.07 (0.01–0.35)
Gender
male 1 
female 0.72 (0.39–1.31) 
Performance status
0–1 1 1 
2 0.05 (0.02–0.11) 0.05 (0.02–0.13)
CCI
0–1 1 1 
2 0.39 (0.20–0.77) 0.36 (0.14–0.91)
Place of residence
urban 1 
rural 1.48 (0.79–2.78) 
In bold statistical signiﬁcant variables with P-value <0.05.
Abbreviations: OR: odds ratio; 95% CI: 95% conﬁdence interval; SES: neighborhood socio
code; CCI: Charlson Cormorbidity Index.
Table 2
Response evaluation and follow-up data of the patient cohort with DLBCL,
diagnosed between 2005 and 2012.
N %





n/a or missing 35 11
Status at last time of follow-up (343)
alive 196 57
death 138 40
lost to follow-up 9 3
Cause of death (138)
DLBCL 79 58
treatment DLBCL 15 11
other 32 23
unknown 12 8
Abbreviations: ICT: immunochemotherapy; CR(u): complete remission (uncon-
ﬁrmed); PR: partial remission; SD: stable disease; PD: progressive disease; n/a: not
applicable; IQR: interquartile range.factors and place of residence were signiﬁcantly associated with
OS. As shown in Table 4, in the ﬁnal multivariable Cox regression
model that included SES, only age, PS  2, elevated LDH, and CCI  2
were independently associated with an increase in mortality risk.
Neighborhood SES did not appear to be a signiﬁcant risk indicator
(Fig. 1).
With SES measured at district level, also no differences in
standard and complete immunochemotherapy was seen between
the three SES groups and it was not signiﬁcantly associated with OS
(data shown in Supplementary Table S5 and S6).
4. Discussion
In this observational, population-based cohort study in patients
with DLBCL, where two third was positioned in a low neighbor-
hood SES, no inequalities were observed in the initiation of
standard immunochemotherapy and the ability to complete
treatment between patients with low, intermediate or high SES.
In addition, SES was no statistically signiﬁcant predictor of overall
survival in this patient cohort. To our knowledge this is the ﬁrst
detailed documentation of treatment across different SES groups
with information in the use of standard treatment protocols in
patients with DLBCL.
Previous reports from the USA reported a strong association
between low SES and inferior outcome in patients with NHL and
particularly with DLBCL [7,12,24]. In elderly patients with NHL low
neighborhood, SES was associated with increased mortality risk,
and differences between ethnic groups were diminished after
correction for neighborhood SES [24]. Low neighborhood SES had a
substantially worse outcome after being diagnosed with DLBCL,
with persistent survival disparities after the introduction of
rituximab. These inequalities were at least partially explained
by inadequate insurance coverage as this might contribute to
limited or delayed access to health care and suboptimal treatment
[7].tients with DLBCL by use of logistic regression models.
Standard ICT completed N = 249
% CI) Crude OR (95% CI) Adjusted OR (95% CI)
1 1
 0.60 (0.25–1.45) 0.51 (0.19–1.37)
 0.55 (0.23–1.34) 0.64 (0.21–1.94)
1 1
 0.12 (0.03–0.52) 0.15 (0.03–0.69)




 0.24 (0.11–0.52) 0.20 (0.08–0.52)
1 1
 0.25 (0.11–0.46) 0.22 (0.10–0.50)
1
1.40 (0.70–2.79)
economic status, divided in low, intermediate and high based on the 4-digit postal
Table 4
Predictors of overall survival in patients with DLBCL with use of a Cox proportional
hazard model.
Crude analysis HR (95% CI) Adjusted analysis HR (95% CI)
SES
low 1 1
intermediate 1.07 (0.66–1.74) 1.31 (0.78–2.18)






60–80 3.42 (1.93–6.07) 3.01 (1.65–5.48)









2 4.35 (3.04–6.24) 3.27 (2.19–4.89)
LDH
normal 1 1
elevated 1.87 (1.32–2.64) 1.92 (1.32–2.78)
CCI
0–1 1 1




*In bold statistical signiﬁcant variables with P-value <0.05.
**Abbreviations: HR: hazard ratio; 95% CI: 95% conﬁdence interval; LDH: lactate
dehydrogenase; CCI: Charlson Comorbidity Index; SES: socioeconomic status.
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differences in socioeconomic disparities in cancer survival in NHL
patients are less clear. A recent population-based study in UK
showed no socioeconomic variations across treatment, stage at
presentation and survival, with use of area-based socioeconomic
data [25]. However, in a large population-based study from
Denmark, socioeconomic inequalities in prognostic markers and
survival in patients with NHL were certainly reported [4,6]. Low
SES, measured at individual level and mainly based on degree of
education, was a predictor for advanced stage disease at time of
diagnosis [4], and increased mortality rates after being diagnosed
with NHL [6]. The presence of more advanced stage disease could
only partially explain this difference. There were no treatment
disparities reported in patients with low, intermediate or high SES
[6] that contributed to survival disparities. However, information
about treatment was missing in up to 29% of the Danish patients
and detailed information about the exact chemotherapeutic
regimes and treatment follow-up were not present. An explanation
for the fact that we did not ﬁnd a worse survival in patients with a
low SES might be the different deﬁnition of SES. While the Danish
study measured SES at an individual educational level, we
measured SES at a neighborhood level. Where a higher educational
level may inﬂuence disease behavior, such as early recognition of
symptoms and ability to comply with medical advice, higher
neighborhood SES reﬂects other (social) factors, such as better
social support, access to health care, and environmental differ-
ences between neighborhoods [26].The presence of more comorbid diseases might be another
explanation for the observed effect of SES on the differences in
treatment and outcome. Several Dutch studies in solid malignan-
cies were published using the same source (SCP) for neighborhood
SES data, for example breast [17], prostate [18], esophageal [19],
gastric [20] and colon cancer [21]. Despite equal health care access,
disparities in treatment or worse survival were noticed in those
with low neighborhood SES. This was at least partially comorbidity
[18,21]. Another large population-based cohort study from the
Netherlands, including patients with NHL, also reported that low
SES is associated with more comorbidity. This could partially
explain the observed relation between lower SES and worse
outcome in patients with cancer [27]. However, as illustrated in our
patients with DLBCL, signiﬁcant comorbidity (CCI  2) was equally
distributed among the different SES. Thus, although we previously
showed that signiﬁcant comorbidity was associated with worse OS
in patients with advanced DLBCL, this risk factor did not negatively
inﬂuenced outcome in patients with low SES in our analysis [8].
This population-based study had several strengths and
limitations. The use of a physician initiated registry, HemoBase,
enabled us to collect complete and representative data for this
region, without the risk of selection bias. The prospective design of
the database provided complete and precise treatment data for all
patients. This study had several limitations when interpreting the
results. First, the sample-size was relatively small. Increasing
sample size will lead to an increased probability of ﬁnding
statistically signiﬁcant effects. However, considering the point
estimates for the hazard ratios of the predictors of OS, there
appeared to be a large difference in these point estimates between
SES and other variables. Thus, increasing the sample size will result
in smaller conﬁdence intervals, but with similar point estimates
there will not lead to a clinical relevant effect. Second, the CCI was
collected retrospectively from the patient medical records. To
minimize the risk for incomplete data, the CCI of all patients were
discussed with the treating clinicians. One of the limitations was
the use of SES at neighborhood level instead of individual level. The
majority of the patients in our cohort was positioned in a low
neighborhood SES. However, this neighborhood SES may not
always precisely represent the socioeconomic circumstances of an
individual patient. While previous studies show that neighbor-
hood SES corresponds well with individual SES [28], another study
shows that area-level socioeconomic disparities in cancer mortali-
ty is only partially explained by individual SES [29]. To verify our
ﬁndings of equal treatment and survival of patients with low SES,
we performed a second analysis with neighborhood SES measured
at smaller quarter level, as this gives a closer approximation of
individual SES, which gave the same results. As a second limitation,
it can be mentioned that neighborhood SES is a composite index
and we had no access to the separate variables that were used in
the factor analysis of this index. However, the use of a composite
index is appropriate, as the separate variables often highly
correlate [26]. Finally, since the majority of the patients in our
cohort had a low SES, our results may not be representative for
other regions in the Netherlands.
5. Conclusion
In this population-based cohort study in patients with DLBCL no
disparities in treatment and survival were seen between patients
with a low, intermediate or high SES. This contrasts with previous
reports and may reﬂect the high-quality standard health care with
equal access in this patient cohort. However, the recently
established nation-wide hemato-oncology registry of the
Netherlands Cancer Registry (NCR) collects detailed data on
demographic, clinical and treatment characteristics of all patients
with hematological malignancies in the Netherlands. Therefore,
Fig. 1. overall survival in patients with low, intermediate and high SES.
K. Boslooper et al. / Cancer Epidemiology 48 (2017) 110–116 115we expect that data from the NCR could be used in the future to
further assess disparities in care across different health care
regions in the Netherlands.
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